Ryan Ho-Yan Wong
Known title: Chief Financial OfficerCIK: 0002079673
Associated companies
Transaction History
| SRPT | ▼ Sell | Tax Withholding | 13,272 | $295K | 9/4/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 256 | $4K | 3/11/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 162 | $3K | 3/9/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 113 | $2K | 3/9/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 450 | $7K | 3/2/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 80 | $2K | 12/1/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 78 | $2K | 12/1/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 93,875 | $0 | 9/3/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 25,000 | $0 | 9/3/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 327 | $5K | 7/31/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Sarepta settles patent dispute with REGENXBIO for $39M
Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.
Sarepta settles patent dispute with REGENXBIO for $39M. Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.